Nephros Inc Stock Price, News & Analysis

Nephros, a leading water technology company, will announce its third-quarter financial results on November 2, 2022, after market close. A conference call is scheduled for 4:30 PM ET the same day, allowing participants to access the call domestically at 1 (844) 808-7106 or internationally at 1 (412) 317-5285. Interested parties can find an audio archive of the call on Nephros' Investor Relations page.

Nephros, Inc. (Nasdaq: NEPH) announced the sale of its Pathogen Detection Systems (PDS) business to BWSI, aiming to reduce cash burn by approximately $350,000 per quarter. The sale includes a seven-year earn-out provision based on gross profits of PDS products. For Q3 2022, Nephros expects net revenue of $2.5 million and an 18% year-over-year increase in active customer sites, reaching 1,391. The company aims for positive net cash flow by mid-2023, ending Q3 with $3.9 million in cash.

Nephros, Inc. (Nasdaq: NEPH) has successfully shipped 3,000 commercial water filters as part of an ongoing contract with Donastar Enterprises LLC and Tractor Beverage Co. This delivery marks a significant milestone following Nephros's approval as a vendor for a major Quick Service Restaurant (QSR) chain. CEO Andy Astor highlighted the positive momentum and potential for further national contracts, indicating growth in Nephros's commercial water filtration business.

Nephros, a water technology company, announced the appointment of Joe Harris to its Board of Directors on September 8, 2022. Harris, who has over 20 years of healthcare sales management experience, expressed enthusiasm about joining Nephros at a pivotal time for the company's growth and sales momentum. Nephros's President and CEO, Andy Astor, highlighted Harris's financial, sales, and marketing expertise. Nephros specializes in filtration and pathogen detection solutions aimed at both healthcare and commercial markets.

Nephros reported a consolidated net revenue of $2.9 million for Q2 2022, marking a 27% increase year-over-year. The water filtration segment generated $2.8 million, a 30% growth compared to the same quarter last year. Active customer sites reached 1,349, up 21%. Despite this revenue growth, Nephros faced a net loss of $1.1 million, consistent with the previous year. Efforts to optimize costs included price increases and operational adjustments, aiming for positive cash flow by mid-2023.

Nephros, Inc. (Nasdaq: NEPH), a leader in water technology solutions, will announce its second-quarter financial results on August 10, 2022, after market close. A conference call will follow at 4:30 PM ET, accessible by dialing 1 (844) 808-7106 for domestic calls and 1 (412) 317-5285 for international participants. A replay will be available until August 17, 2022. Nephros focuses on innovative filtration and pathogen detection technologies that serve healthcare and commercial markets, aiming to enhance water safety and management.

Nephros, Inc. (Nasdaq: NEPH) reported a preliminary revenue of $2.9 million for Q2 2022, marking a 27% increase year-over-year. The number of Active Customer Sites grew by 21% from 1,117 to 1,349. CEO Andy Astor expressed optimism regarding revenue growth, supported by a strong sales pipeline and an expense management plan aimed at achieving positive net cash flow within the next 12 months. The company ended the quarter with approximately $4.2 million in cash. Q2 results will be officially announced on August 10, 2022.

Nephros, Inc. (Nasdaq: NEPH) announced FDA 510(k) clearance for its HDF Assist Module, the first device in the U.S. to provide hemodiafiltration therapy for End-Stage Renal Disease patients. This milestone allows Nephros to enhance treatment options for patients without needing new, expensive equipment. The module will be piloted in select dialysis clinics to establish operational procedures and train staff. Nephros aims to improve water safety through innovative technology, serving both healthcare and commercial sectors.

Nephros, Inc. (NASDAQ: NEPH) reported a net revenue of $2.2 million for Q1 2022, a 20% decrease from the previous year. The company faced a net loss of $2 million, significantly up from $0.5 million in Q1 2021, reflecting a 266% increase in losses. Adjusted EBITDA was (1.5 million), worsened from (0.7 million) last year. Despite these downturns, active customer sites grew 17% year-over-year to 1,276. Nephros withdrew its 2022 revenue guidance due to unexpected market conditions but expressed optimism about future growth.